Difference between revisions of "Waldenström macroglobulinemia - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. " to "") |
m |
||
| Line 17: | Line 17: | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen variant #1 {{#subobject:82d5c8|Variant=1}}=== | ===Regimen variant #1 {{#subobject:82d5c8|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | ||
| + | |2009-03-17 to 2011-02-24 | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 34: | Line 36: | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen variant #2 {{#subobject:839bc8|Variant=1}}=== | ===Regimen variant #2 {{#subobject:839bc8|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | ||
| + | |2009-03-17 to 2011-02-24 | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 50: | Line 54: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 | + | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701--> |
# '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971/ PubMed] [https://clinicaltrials.gov/study/NCT00811733 NCT00811733] | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971/ PubMed] [https://clinicaltrials.gov/study/NCT00811733 NCT00811733] | ||
| Line 57: | Line 61: | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen variant #1 {{#subobject:81ncy8|Variant=1}}=== | ===Regimen variant #1 {{#subobject:81ncy8|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | ||
| + | |2009-03-17 to 2011-02-24 | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 74: | Line 80: | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen variant #2 {{#subobject:8a0bj8|Variant=1}}=== | ===Regimen variant #2 {{#subobject:8a0bj8|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] | ||
| + | |2009-03-17 to 2011-02-24 | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 90: | Line 98: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 | + | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 --> |
# '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971/ PubMed] [https://clinicaltrials.gov/study/NCT00811733 NCT00811733] | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971/ PubMed] [https://clinicaltrials.gov/study/NCT00811733 NCT00811733] | ||
| Line 96: | Line 104: | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen {{#subobject:2221fe|Variant=1}}=== | ===Regimen {{#subobject:2221fe|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ Ghobrial et al. 2013 (DFCI 09-071)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ Ghobrial et al. 2013 (DFCI 09-071)] | ||
| + | |2009-07 to 2011-03 | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 111: | Line 121: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''DFCI 09-071:''' Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. [ | + | # '''DFCI 09-071:''' Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. [https://doi.org/10.1182/blood-2012-06-439307 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23287861/ PubMed] [https://clinicaltrials.gov/study/NCT00936611 NCT00936611] |
[[Category:Waldenström macroglobulinemia regimens]] | [[Category:Waldenström macroglobulinemia regimens]] | ||
Latest revision as of 18:30, 27 June 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? Please go to the main WM regimen page to find other regimens.
3 regimens on this page
5 variants on this page
|
First-line therapy
Ofatumumab monotherapy
Regimen variant #1
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Furman et al. 2016 (GSK 110921) | 2009-03-17 to 2011-02-24 | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Furman et al. 2016 (GSK 110921) | 2009-03-17 to 2011-02-24 | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains dosing details in abstract link to PMC article PubMed NCT00811733
Relapsed or refractory
Ofatumumab monotherapy
Regimen variant #1
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Furman et al. 2016 (GSK 110921) | 2009-03-17 to 2011-02-24 | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Furman et al. 2016 (GSK 110921) | 2009-03-17 to 2011-02-24 | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains dosing details in abstract link to PMC article PubMed NCT00811733
Panobinostat monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Ghobrial et al. 2013 (DFCI 09-071) | 2009-07 to 2011-03 | Phase 2 |
Targeted therapy
- Panobinostat (Farydak) 30 mg PO 3 days per week (Mondays, Wednesdays, and Fridays)
28-day cycles
References
- DFCI 09-071: Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00936611